lorecivivint (SM04690)

News alerts, weekly reports and conference planners

Company:

Biosplice Therap, Samil Pharma

Drug class:

Wnt signalling pathway inhibitor, pan-CLK inhibitor, DYRK1A inhibitor

Related drugs:

CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	PRI724 + SM04690 Sensitive: B - Late Trials PRI724 + SM04690 Sensitive : B	PRI724 + SM04690 Sensitive: B - Late Trials PRI724 + SM04690 Sensitive : B
CTNNB1 mutation	Endometrial Cancer	CTNNB1 mutation	Endometrial Cancer	SM04690 Sensitive: B - Late Trials SM04690 Sensitive : B	SM04690 Sensitive: B - Late Trials SM04690 Sensitive : B

Associations
(2)